Laboratory Medicine Program

Acute Leukemia: FLT3/NPM1 (new AML diagnosis)

Clinical Decription:
Mutations in the NPM1 gene define a specific acute myeloid leukemia (AML) entity associated with an overall good outcome. Mutations in the FLT3 gene such as internal tandem duplications (ITD) or variants in the tyrosine kinase domain (TKD) are frequent in AML. FLT3-ITD and FLT3-TKD are sensitive to AML drugs. The presence of additional co-occurring FLT3-ITD or FLT3-TKD variants can influence clinical management of AML. Multiplex PCR with primers targeting the NPM1 mutation as well as the FLT3-ITD and FLT3-TKD variants is performed for diagnosis and clinical management of AML.

Method: PCR

Component Tests Used: n/a

Reference Ranges Used:
Reference ranges for this test are not available online. However, they are included in all test results. For more information, please call us.

Specimen Type: Bone Marrow aspirate
Collected In: EDTA
Volume: 1-2 mL (minimum: 1 mL)

Shipping: room temperature or 4C

Special Instructions: See requisitions for the full list of available testing and special instructions.

Testing Schedule(s): Please call

Turnaround Time: None

For more information, call 416.340.5227 or 1.866.865.5227